HIV Vaccine: MIT One-Shot Breakthrough
- A novel approach to HIV vaccination, employing a single dose with two powerful adjuvants, has demonstrated a strong immune response in early trials.
- the experimental vaccine, combining alum and SMNP adjuvants, accumulated in the lymph nodes of mice for nearly a month.
- Christopher Love, a professor of chemical engineering at MIT, noted the broad applicability of the method.
MIT scientists achieve a breakthrough with a single-dose HIV vaccine, sparking hope in the fight against the virus. Early trials reveal a powerful immune response in mice,thanks to a novel dual-adjuvant approach. this groundbreaking research, combining alum and SMNP adjuvants, generated a broader range of HIV antibodies. The vaccine’s method allowed the antigen to remain intact in lymph nodes for extended periods,stimulating B cells for more effective antibody development.This innovative strategy may perhaps lead to single-dose vaccines against HIV and other infectious diseases. According to News Directory 3, the team aims to explore long-term efficacy and safety, considering applications for influenza, SARS-CoV-2, and future outbreaks. Discover what’s next …
Single-dose HIV Vaccine Shows Promise with Dual Adjuvant Approach
Updated June 21, 2025
A novel approach to HIV vaccination, employing a single dose with two powerful adjuvants, has demonstrated a strong immune response in early trials. Researchers from MIT and the Scripps Research Institute report that the dual-adjuvant vaccine generated a wider range of antibodies against HIV in mice, compared to vaccines with a single adjuvant or none at all.
the experimental vaccine, combining alum and SMNP adjuvants, accumulated in the lymph nodes of mice for nearly a month. This prolonged exposure allowed the immune system to develop a greater number of antibodies targeting the HIV protein. The findings suggest a potential pathway toward single-dose vaccines for HIV and other infectious diseases, including SARS-CoV-2.
J. Christopher Love, a professor of chemical engineering at MIT, noted the broad applicability of the method. ”This approach is compatible with many protein-based vaccines,” Love said, “so it offers the chance to engineer new formulations for these types of vaccines across a wide range of different diseases, such as influenza, SARS-CoV-2, or other pandemic outbreaks.”
The study, published in Science Translational Medicine, explored the synergistic effects of alum and SMNP. Darrell Irvine, a professor of immunology and microbiology at the Scripps Research Institute, collaborated with Love on the research. Kristen Rodrigues and Yiming Zhang are listed as lead authors.
researchers found that the combination of SMNP and alum facilitated the penetration of the HIV antigen through the protective cell layer surrounding the lymph nodes, preventing its breakdown. This allowed the antigens to remain intact within the lymph nodes for up to 28 days, continuously stimulating B cells.
Love explained that the prolonged exposure allows B cells to refine thier response. “Consequently, the B cells that are cycling in the lymph nodes are constantly being exposed to the antigen over that time period, and they get the chance to refine their solution to the antigen,” Love said.
analysis of B cells from vaccinated mice revealed a more diverse repertoire of antibodies in those receiving the dual-adjuvant vaccine. This increased diversity raises the likelihood of generating broadly neutralizing antibodies capable of recognizing various HIV strains.
What’s next
The research team plans to further investigate the long-term efficacy and safety of the single-dose HIV vaccine approach, with the goal of translating these findings into human clinical trials. The dual adjuvant strategy may also be applied to develop more effective vaccines against other challenging infectious diseases.